Note: ResQ Biotech programs are investigational and not approved for use; efficacy and safety have not been established.
ResQ Biotech is advancing a pipeline of first-in-class, disease-modifying therapies designed to correct pathogenic protein conformations at their root. The lead programs target tau in Alzheimer's disease and related tauopathies, and SOD1 in ALS.
Note: ResQ Biotech programs are investigational and not approved for use; efficacy and safety have not been established.